HIV Vaccines

HIV/SIV Vaccine Studied in Primate Model

Published in AIDS Weekly, March 6th, 2000

HIV/SIV can be attenuated through the gain of IkappaB-(alpha)S32/36A, a proteolysis-resistant inhibitor of NF-kappaB, reported researchers from Italy.

"Live-attenuated SIVs deleted of accessory genes such as nef, vpr, vpx, and upstream region of LTR have been used as vaccine candidates for AIDS in monkeys," said Antimina Puca and colleagues from the Dipartimento di Biochimica e Biotecnologie Mediche, Italy. "This vaccine approach conferred protective immunity against pathogenic SIV; however, it raised serious concerns due to pathogenic mutants which were generated after in vivo replication of the live-attenuated virus vaccine. Hence, additional...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2000-03-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry